Peramivir Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 200 mg
Reference Brands: Rapivab (USA)
Category:
Anti Viral
Peramivir is available in Injection
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Peramivir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Peramivir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Peramivir is an antiviral medication used for the treatment of influenza and is marketed under the trade name Rapivab. It was developed by BioCryst Pharmaceuticals and belongs to the neuraminidase inhibitor class of antiviral agents. Peramivir works by acting as a transition-state analogue inhibitor of the influenza neuraminidase enzyme, which plays a key role in the release of newly formed viral particles from infected host cells. By blocking this enzyme, peramivir limits viral replication and helps reduce the spread of the virus within the respiratory tract.
Unlike other neuraminidase inhibitors that are administered orally or by inhalation, peramivir is approved exclusively for intravenous administration. This route of delivery makes it particularly valuable for hospitalized patients, critically ill individuals, or patients who are unable to take oral medications. Peramivir is primarily indicated for the treatment of acute uncomplicated influenza caused by influenza A and B viruses.
The intravenous formulation allows for rapid achievement of therapeutic drug levels and provides a reliable treatment option in clinical settings requiring immediate antiviral intervention. Peramivir is generally used as a single-dose or short-course therapy under medical supervision, especially during seasonal influenza outbreaks or in severe cases requiring inpatient care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing